Comparative Pharmacology
Head-to-head clinical analysis: SOLIRIS versus ZIRABEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOLIRIS versus ZIRABEV.
SOLIRIS vs ZIRABEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
ZIRABEV (bevacizumab-awwb) is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A and prevents its interaction with VEGFR-1 and VEGFR-2 receptors on endothelial cells, thereby inhibiting angiogenesis.
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (aHUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
15 mg/kg intravenously over 60 minutes on Day 1 of each 3-week cycle
None Documented
None Documented
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Terminal elimination half-life is approximately 20 days (range 11-50 days). This long half-life supports extended dosing intervals (e.g., every 2-3 weeks).
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
ZIRABEV (bevacizumab) is eliminated primarily via metabolic degradation in the reticuloendothelial system. Renal excretion is minimal (<1% as unchanged drug in urine). Biliary/fecal excretion accounts for the remainder of metabolites.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody